HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 03, March 2019 – Driven by curiosity — Exclusive interview with Nobel laureate Ada Yonath: Her journey in science wasn't always crystal clear       » Your eyes don't deceive you, your brain does       » Organ donations to be computerised in China       » Over One tenth of Chinese people have mental health problems       » AI system can diagnose childhood diseases like doctors       » Bitter rapeseed potential protein source for human nutrition      
EYE ON CHINA
Chinese patients to see more affordable, high-quality generic drugs
CFDA brings total number of China’s domestic generic drugs to 57

The China Food and Drug Administration recently announced that 16 more generic drugs have been proven equivalent to their original counterparts in both quality and efficacy, bringing the total number of such drugs to 57, People’s Daily Overseas Edition reported on 31 July 2018.

The Generic Quality Consistency Evaluation (GQCE), which has been carried out in China since 2015, is a mandatory bioequivalence test that promotes the quality of China’s domestic generic drugs.

An expert in the field said that the implementation of GQCE is expected to expand the domestic market, create a favourable development environment and promote fair competition for generic drugs, thus helping to lower drug prices.

In April, the Chinese government released a circular focused on improving the supply and utilisation of generics, promoting the quality and efficacy of generic drugs, speeding up the implementation of the GQCE and enhancing quality control of drugs.

According to the circular, the country will provide favourable policies and support to qualified generic drugs in purchasing, pricing, medical insurance coverage and investment. Medical institutions should also give high priority to the use of generic drugs in clinical practice.

According to the GQCE, after the first three manufacturers of a kind of drug pass the assessment stage, no other drug manufacturers will be granted a license to make this drug for the following three years.

An industry insider pointed out that the GQCE is a challenge for domestic generic drug manufacturers, because its implementation will reduce the number of generic drugs on the market by 60 percent. The assessment will, however, motivate manufacturers as the industry becomes normalised and institutionalised.

More than 10 Chinese cities have enacted policies to support the registration of approved generic drugs. For instance, Hubei province in central China has granted a “green passage” to simplify procedures when it comes to introducing approved generic drugs in hospitals.

Source: People’s Daily

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy